ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LUCD vs MBOT // REVENUE GROWTH (YOY)

Lucid Diagnostics Inc. (NASDAQ) VS. Microbot Medical Inc. (NASDAQ) • 15-METRIC TALLY: LUCD 1 — MBOT 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LUCD VS. MBOT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LUCD MBOT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -15.80% -19.20 MBOT /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -17.42% — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.8 42.6 -5.80 MBOT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $82.6M $69.9M $12.7M LUCD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LUCD REV MBOT REV LUCD GROSS % MBOT GROSS % LUCD FCF MBOT FCF
FY 2025 $139.0M $41.3M — — -$46.7M -$13.1M
FY 2024 $4.3M $32.5M -50.0% — -$44.4M -$8.9M
FY 2023 $2.4M $27.6M — — -$32.8M -$8.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LUCD // BETA —
MBOT // BETA —